Coronavirus vaccine: Positive results found after the trial run ‘Remdesivir’ drug

The US government’s top physician and immunologist Dr. Anthony Stephen Fauci says. He is optimistic about the positive preliminary Positive results found after the trial run of the experimental treatment of coronavirus with Remdesivir drug.

Fauci’s activities led to the discovery of antiviral drugs for HIV. That Fauci claims that in the United States, remediation is acting as a shield on the body of  COVID-19 remdesivir drug trial positive. The antiviral drug has been administered to more than 1,690 people in the United States, according to said him. Observations revealed that Compared to common medicine Patients who were treated with Remdesivir drugs took less than 30 percent of the time to recover. Previously applied medications took 15 days to prevent coronavirus and after applying for Remdesivir drugs, it takes 4 days to recover.

In The White House press briefing Dr. Anthony Stephen Fauci (left) says about coronavirus recharge proggers in media. On the right side stand President Donald Trump

An American pharmaceutical company called Gilead has issued a statement regarding the drug Remdesivir they produce. The statement said “positive data” was found after a trial run by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States, and that the test “achieved their initial goal.”

The Gilead pharmaceutical company reports that  Remdesivir medicine has been worked to prevent from Covid-19. it is an antiviral medication that was created to treat Ebola. However, the company indicates that the earlier the Remdesivir is given, the more effective it is. Gilead states, “It has been possible to release 62 percent of the patients who have been dealt with already. And 49 percent of the patients who were given late has left the hospital.

Gilead’s share price rose more than 6 percent on Wednesday after US President Trump praised the drug as “positive.” Anthony Fauci, a doctor with the U.S. Coronavirus Task Force, said the initial results were very promising. However, scientists in many countries have disagreed on the effectiveness and success of this drug.

Prior to the announcement, the science magazine The Lancet quoted a test by Remedisevir in China as saying that this drug did not work – but the survey was not completed because there were not enough patients at the time.

Gilead pharmaceutical companies deadly COVID-19 research team members

Dr. Amitabh Nandi, a prominent virologist leading with Remdesivir, says, “Clinical trials have their own complications. I don’t know how much it should be said that a drug works in such a short time for a disease like a coronavirus. Large-scale multicentric randomized clinical trials are needed before any drug can be marketed. Which has to do with different people from different continents. That examination will be totally fair-minded and reconstructive. The whole thing is quite time-consuming.”

He added that clinical trials of any new disease drug usually require two things to keep in mind. Preclinical and clinical trials must need for new drugs. In preclinical trials, the drug is administered to the animal in accordance with the protocol. At the point when that work is finished, it is the turn of the clinical preliminary. The Drug Control Board has decided on that as well. Clinical preliminaries are in the human body.

For this situation, the researchers structured a particular report before the preliminary. A group is then told, you are being given this medicine. The other group was not given any information about the drugs. They apply the medicine to the infected patient just like the usual medicine. The new drug is given a green signal after reviewing whether the drug is causing any poisoning or side effects.